UK
Health analytics
Broader value of medicines and health
The ways in which we assess and pay for medicines and technologies reflect only the partial value that good health brings to healthcare systems and broader society. To ensure optimal allocation of limited resources, we must align incentives around the full value of health, incorporating both its direct and indirect benefits for the economy and society as a whole.
Healthcare payers worldwide are faced with difficult decisions about funding new medicines and treatment innovations against a backdrop of constrained budgets and resources
Governments and payers seek reassurance that investment in health is both affordable and represents good value for money. However, the perspective on value adopted by most healthcare decision-makers is narrow, focusing only on cost savings to the healthcare system and outcomes on an individual patient level.
At LCP, we believe that if decision-makers broaden their horizons, and consider a more holistic assessment of treatment value, this will lead to improved allocation of resources.
For example, many governments globally are faced with growing economic inactivity. Healthcare innovations can keep people in employment or support people outside the workforce in returning to work. This benefits economies in terms of both improved net productivity as well as reduced social support costs.
Further, traditional methods look at outcomes at the aggregate population level, and generally fail to consider whether new technologies or policies improve or exacerbate existing inequalities.
These considerations, among others, have been proposed in recent “inventories” of value elements put forward by ISPOR (International Society for Pharmacoeconomics and Outcomes Research) and the Second Panel on Cost-Effectiveness in Health and Medicine. The ISPOR value flower, for example, incorporates “petals” representing core elements of value (net costs and quality-adjusted life years (QALYs) gained) as well as potential novel elements, including equity, insurance value, and scientific spillovers. Recent methodological papers are building on this established framework with recommended approaches to incorporating individual, or combined, value element petals.
We help our life sciences clients include broader value as part of their market access evidence strategies
We work with our clients to look at the broader value of medicines and health, realigning how health technology assessment (HTA) organizations and governments value medicines and the value of health to patients, populations, and economies.
We do this by developing innovative, high-value payer-grade and policy-maker evidence with a particular emphasis on broader and emerging value elements such as equity and net productivity.
We work with clients in these key ways:
- Assessing the net productivity impact of healthcare interventions using established frameworks (e.g. the UK Department of Health and Social Care’s Wider Societal Impacts model, and the Institute for Clinical and Economic Review's (ICER) recommended approach for valuing patient and caregiver productivity time by Jiao & Basu, 2023) alongside bespoke solutions.
- Developing both qualitative and quantitative evidence to demonstrate the equity impacts of medicines, technologies, or health policies. This includes the implementation of methods such as Distributional Cost Effectiveness Analysis, cognizant of the challenges facing HTA organizations and payers in assessing such evidence.
- Articulating the fiscal value of prevention and treatment measures by quantifying the social support benefits savings that would be realized by preventing a person from falling out of work due to illness.
- Quantifying the insurance value of having a treatment available in case of a future major or rapidly escalating health problem.
- Capturing the impact of healthcare interventions on caregivers as well as the patients themselves.
- Modeling potential impacts of interventions on wait lists and linking this to patient, healthcare system and societal outcomes.
We know that change requires partnerships and so at LCP we help to drive collaboration across industry, academia, and HTA organizations/payers to ensure tractable progress to move towards a more holistic assessment.
Medicines Nexus™
Prescription analytics platform
Our innovative prescription analytics platform delivering cutting-edge insights into the medicines market.
Explore our range of services
Real-world evidence generation
We work closely with clients to meet the growing demand for rigorous and impactful real world evidence.
Health economic outcomes research
We support you in thoroughly evaluating and clearly communicating your product’s value.
Global market access strategy
We help you navigate uncertainty and maximize value across product development and commercialization.
US access solutions
We provide integrated US market access solutions using analytics, clinical insight, and strategic consulting to support pharma success.
Medical and public affairs
We empower medical and public affairs teams to identify and act on opportunities for health system transformation.
Featured insights
Most Favored Nation clause: Why revising differential pricing may be wiser than importing global prices
Kevin Patterson, US Access Solutions, LCP and William Lob, Vice President, Strategic Initiatives PRMA, Indegene, discuss why the MFN clause may undermine US drug pricing sovereignty.
Reimagining patient support in the era of MFN: A strategic imperative for manufacturers
Lee Ann Steadman explores how the Most Favored Nation (MFN) policy is reshaping drug pricing and why manufacturers must reimagine patient support programs as strategic, sustainable models to protect access and deliver long-term value.
Achieving equitable representation in clinical trials
Matthew Hankins examines how integrating real-world evidence into diversity action plans can help clinical trial sponsors comply with FDA diversity guidance.
Recognizing the broader value of caregiving in healthcare
Explore how caregiver value is being captured, how it varies across therapeutic areas and countries, and why it is increasingly critical for shaping evidence generation, access decisions, and value-based healthcare delivery.
Get in touch
Contact us to learn more about how we can provide clarity and insight in today’s increasingly complex life sciences and healthcare environment.
